Entries by Healthcare Team

Poolbeg Pharma plc – MHRA grants Clinical Trial Authorisation for the TOPICAL trial and independent research confirms significant commercial opportunity for POLB 001

/in

Trial on track to deliver interim data this summer 15 April 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has granted Clinical Trial Authorisation (“CTA”) for the POLB 001 TOPICAL trial. With all required […]

Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development

/in

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized immune response against a patient’s tumors, despite being an off-the-shelf drug Asgard is currently progressing IND-enabling studies of this first-in-class therapy, which reprograms cancer cells in vivo, […]

Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments

/in

Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief Scientific Officer Janine Schuurman, PhD, Hans Clevers, MD, PhD, and David Sansom, PhD, join the Scientific Advisory Board Appointments strengthen Laigo’s leadership team following its €17m seed financing as the Company advances its SureTACs™ programs towards clinical development UTRECHT, […]

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting

/in

— MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors Cambridge, UK, April 14, 2026 – Mestag Therapeutics, a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory disease, announced today that it has been […]

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

/in

First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program Montreal, Canada – Strasbourg, France – Boston, United States, April 9, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

© Optimum Strategic Communications.